24452-07-1

Upstream product

• 30626-03-0 (3E)-4-(4-chlorophenyl)-3-buten-2-one 
• 27032-03-7 1-(ethoxycarbonylmethyl)pyridinium chloride 

Downstream Products

• 917969-67-6 3-bromo-4-(4-chlorophenyl)-2-hydrazinyl-6-methylpyridine 
• 917969-73-4 3-bromo-6-chloro-4-(4-chlorophenyl)-2-methylpyridine 
• 917969-66-5 3-bromo-2-chloro-4-(4-chlorophenyl)-6-methylpyridine 
• 917969-68-7 8-bromo-7-(4-chlorophenyl)-5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 917969-72-3 5-bromo-4-(4-chlorophenyl)-6-methylpyridin-2(1H)-one 
• 917969-65-4 3-bromo-4-(4-chlorophenyl)-6-methylpyridin-2(1H)-one 

Relevant academic research and scientific papers

Triazolopyridine cannabinoid receptor 1 antagonists

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGIUR2 ANTAGONISTS

The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders:wherein A, B, X, Y, R1, R2, R3 and R4 are as defined in the description and claims.